CV Science

Yann-Gael Gangloff PhD Biochemistry & Molecular and Cellular Biology

Course and current status

RESEARCH

Since 2016     Researcher: PI3K/mTOR signaling in muscle -  Institut NeuroMyoGène (INMG) - CNRS UMR 5310 - INSERM U1217

2004-2015    Researcher: PI3K/mTOR signaling in muscle -  Laboratory of Molecular Biology of the Cell (LBMC) at the Ecole Normale Supérieure de Lyon (UMR5239, CNRS/ENS).

2001 – 2004     Post-doctoral Fellow at the Friedrich Miescher Institute (FMI), Basel, Switzerland. Laboratory: Dr. G. Thomas.

2001         PhD student at the Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC), Strasbourg, France. Laboratory: Dr. I. Davidson. PhD Thesis entitled: Structural and functional analysis of the general transcription factor TFIID in yeast and mammals.

EDUCATION

1997 – 2001 Graduate Studies in Molecular and Cellular Biology, University Louis-Pasteur, Strasbourg, France.

1996 – 1997     Master Thesis in Molecular and Cellular Biology, University Louis-Pasteur, Strasbourg, France.

1991 – 1995     Studies of Biochemistry & Molecular and Cellular Biology, University Louis-Pasteur, Strasbourg, France.

COLLOQUIUM AND WORKSHOP

Nov. 2010 Biochemical Society Meeting: mTOR signaling in health and disease, London, UK.

Sept. 2010 MYOAGE Workshop: Tor, caloric restriction and anabolism in ageing, Split, Croatia.

Sept. 2008 Biochemical Society Meeting: mTOR signaling, nutrients and disease, Oxford, UK.

May 2008 International Congress of Myology 2008, Marseille, France.

Scientific summary

Our work focuses on the mTOR signaling pathway, a molecular integrator of nutrients, stress, growth factors and hormones, such as IGF-1 and insulin. mTOR hyperactivation is implicated in the progression of stress-associated phenotypes and diseases, such as aging, tumorigenesis, obesity and diabetes. Several classes of mTOR-targeted therapeutics are currently being evaluated in cancer clinical trials, including rapamycin analogs, dual PI3K-mTOR inhibitors, and ATP-competitive mTORC1/2 inhibitors. mTOR inhibitors are likely to be extended in the management of metabolic syndromes, anti-aging therapy, cardiomyopathy and neurodegeneration.
In striated muscles, we and others demonstated that mTOR is as a central regulator of muscle growth, metabolism and integrity.
The aim of our research is to establish the roles of mTOR in muscle plasticity, physiology and pathology.

We are looking for enthusiastic and skilful PhD  and post-doctoral candidates. Contact: yann-gael.gangloff@ens-lyon.fr - Ecole Normale Supérieure (ENS)-Laboratory of Molecular and Cellular Biology (LBMC)-Université de Lyon-69364 Lyon Cedex 07, France